Chronic Hepatitis C

Infectious Diseases
72
Pipeline Programs
19
Companies
50
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
18
2
19
2
19
12
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
12100%
+ 68 programs with unclassified modality

On Market (4)

Approved therapies currently available

Roche
COPEGUSApproved
ribavirin
Roche
oral2002
M&
REBETOLApproved
ribavirin
Merck & Co.
oral1998
U
RIBAVIRINApproved
ribavirin
Unknown Company
Nucleoside Analog Antiviral [EPC]oral2009
GS
SOVALDIApproved
sofosbuvir
Gilead Sciences
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]oral2013

Competitive Landscape

18 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
18 programs
3
1
3
1
2
4
PioglitazonePhase 41 trial
RibavirinPhase 41 trial
SOF/LDVPhase 41 trial
grazoprevir and elbasvirPhase 4Small Molecule1 trial
Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tabletsPhase 31 trial
+13 more programs
Active Trials
NCT03088917Completed106Est. Dec 2019
NCT01402583Completed1,000Est. Sep 2011
NCT00736242Completed232Est. Dec 2011
+19 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
13 programs
3
1
2
2
SOF/LDVPhase 4
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirinPhase 41 trial
ABT-493/ABT-530Phase 31 trial
ombitasvir/paritaprevir/ritonavirPhase 3Small Molecule1 trial
ABT-493, ABT-530Phase 2/31 trial
+8 more programs
Active Trials
NCT02582671Completed101Est. Nov 2017
NCT02581189Completed565Est. Dec 2017
NCT03693586Completed1,000Est. Mar 2022
+10 more trials
GS
Gilead SciencesFOSTER CITY, CA
10 programs
2
2
4
1
SOFPhase 31 trial
SOFPhase 31 trial
SOVALDI(SOF)Phase 31 trial
SofosbuvirPhase 3Small Molecule1 trial
LDV/SOFPhase 21 trial
+5 more programs
Active Trials
NCT04208035Unknown250Est. Jan 2021
NCT01817985Completed33Est. Aug 2013
NCT02202980Completed273Est. May 2016
+5 more trials
Roche
RocheSTAVANGER NORWAY, Norway
5 programs
1
3
1
Pegylated interferon and ribavirinPhase 41 trial
peg interferon plus ribavirinPhase 31 trial
pegylated interferon alpha2aPhase 31 trial
ribavirinPhase 31 trial
ANA598 200 mg bid or placeboPhase 11 trial
Active Trials
NCT00782353Completed35Est. Mar 2009
NCT00296972Terminated100Est. Apr 2007
NCT00158496Completed100Est. Jan 2005
+2 more trials
CP
Chugai PharmaJapan - Tokyo
2 programs
1
1
Pegasys®Phase 41 trial
peginterferon alfa-2aPhase 31 trial
Active Trials
NCT00144469Completed300Est. Mar 2005
NCT00245414Completed108Est. Jul 2010
VP
10 programs
4
5
1
MP-424Phase 31 trial
RibavirinPhase 21 trial
TelaprevirPhase 2Small Molecule1 trial
VX-135Phase 21 trial
VX-135Phase 21 trial
+5 more programs
Active Trials
NCT00591214Completed10Est. Oct 2008
NCT01704521Completed5Est. Oct 2014
NCT01144936Completed21Est. Oct 2010
+7 more trials
Novartis
NovartisBASEL, Switzerland
5 programs
1
2
2
albumin interferon alfa-2bPhase 31 trial
albumin interferon alfa-2bPhase 31 trial
NM283 plus Peg-IFNα-2aPhase 2
alb-interferon alfa 2bPhase 21 trial
Albinterferon alfa 2bPhase 11 trial
Active Trials
NCT00724776Completed30
NCT00759200Completed525Est. Dec 2010
NCT00411385Completed933Est. Oct 2008
+1 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
5 programs
1
4
Daily InfergenPhase 31 trial
Daily InfergenPhase 31 trial
ViramidinePhase 31 trial
ViramidinePhase 31 trial
TaribavirinPhase 21 trial
Active Trials
NCT00446134CompletedEst. Apr 2009
NCT00162734CompletedEst. Jun 2007
NCT00086541CompletedEst. Jan 2007
+2 more trials
Debiopharm
DebiopharmSwitzerland - Lausanne
2 programs
1
Debio 025Phase 21 trial
Debio 025N/A1 trial
Active Trials
NCT00854802CompletedEst. Sep 2010
NCT00537407CompletedEst. Apr 2010
Cocrystal Pharma
Cocrystal PharmaBOTHELL, WA
1 program
1
CDI-31244Phase 21 trial
Active Trials
NCT03501550CompletedEst. Jun 2019
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
PPI-668Phase 21 trial
Active Trials
NCT01859962Completed38Est. Dec 2014
Teva
TevaIsrael - Petach Tikva
1 program
1
CT-011Phase 1/21 trial
Active Trials
NCT00962936Terminated13Est. Jan 2013
Bristol Myers Squibb
2 programs
2
BMS-790052Phase 15 trials
BMS-824393Phase 11 trial
Active Trials
NCT02161939No Longer Available
NCT02097966No Longer Available
NCT01492426Completed605Est. Mar 2014
+3 more trials
Atea Pharmaceuticals
1 program
1
AT-527Phase 11 trial
Active Trials
NCT03219957CompletedEst. Jun 2018
Opko Health
Opko HealthMIAMI, FL
1 program
1
EMZ702Phase 11 trial
Active Trials
NCT00230854CompletedEst. Jul 2007
Genentech
GenentechCA - Oceanside
1 program
1
PegInterferonPhase 1
Dynavax Technologies
Dynavax TechnologiesCA - Emeryville
1 program
1
SD-101Phase 11 trial
Active Trials
NCT00823862Completed34Est. Feb 2010
Pfizer
PfizerNEW YORK, NY
1 program
1
filibuvirPhase 1Small Molecule1 trial
Active Trials
NCT01210404Completed12Est. Jun 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.grazoprevir and elbasvir
Merck & Co.SOF/LDV
AbbVieparitaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
Merck & Co.Ribavirin
Merck & Co.Pioglitazone
Chugai PharmaPegasys®
RochePegylated interferon and ribavirin
AbbVieABT-493/ABT-530
AbbVieABT-450/r
AbbVieombitasvir/paritaprevir/ritonavir
Merck & Co.Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
Gilead SciencesSOF
Gilead SciencesSofosbuvir
Gilead SciencesSOF
Gilead SciencesSOF

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 11,108 patients across 50 trials

NCT03098121Merck & Co.grazoprevir and elbasvir

Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection

Start: Oct 2017Est. completion: Nov 201840 patients
Phase 4Completed
NCT02786537Merck & Co.SOF/LDV

Study of Oral Treatments for Hepatitis C

Start: Jun 2016Est. completion: Sep 20201,275 patients
Phase 4Completed
NCT03710252AbbVieparitaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study

Start: Mar 2016Est. completion: Sep 2017100 patients
Phase 4Completed
NCT01731301Merck & Co.Ribavirin

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

Start: Jan 2013Est. completion: Jan 201520 patients
Phase 4Unknown
NCT01025765Merck & Co.Pioglitazone

The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin

Start: Nov 2009Est. completion: Dec 201280 patients
Phase 4Unknown
NCT00245414Chugai PharmaPegasys®

Trial of Pegasys® in Patients With Chronic Hepatitis C

Start: Oct 2005Est. completion: Jul 2010108 patients
Phase 4Completed
NCT01120795RochePegylated interferon and ribavirin

Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy

Start: Feb 2004Est. completion: Jul 200655 patients
Phase 4Completed
NCT02604017AbbVieABT-493/ABT-530

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Start: Oct 2015Est. completion: Jan 2017703 patients
Phase 3Completed
NCT02265237AbbVieABT-450/r

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)

Start: Oct 2014Est. completion: Apr 2017184 patients
Phase 3Completed
NCT02207088AbbVieombitasvir/paritaprevir/ritonavir

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Start: Sep 2014Est. completion: Dec 201668 patients
Phase 3Completed
NCT02105662Merck & Co.Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

Start: Jun 2014Est. completion: May 2015218 patients
Phase 3Completed
NCT01604850Gilead SciencesSOF

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

Start: Jun 2012Est. completion: May 2013202 patients
Phase 3Completed
NCT01641640Gilead SciencesSofosbuvir

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Start: Jun 2012Est. completion: Apr 2013328 patients
Phase 3Completed
NCT01625338Gilead SciencesSOF

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Start: Jun 2012Est. completion: Dec 2014534 patients
Phase 3Completed
NCT01542788Gilead SciencesSOF

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

Start: Mar 2012Est. completion: Feb 2013278 patients
Phase 3Completed
NCT01492426Bristol Myers SquibbBMS-790052

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

Start: Jan 2012Est. completion: Mar 2014605 patients
Phase 3Completed
NCT01457937Merck & Co.Pegylated Interferon, Ribavirin, Boceprevir

Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)

Start: Nov 2011Est. completion: Jun 2014240 patients
Phase 3Unknown
NCT00780910Vertex PharmaceuticalsMP-424

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Start: Nov 2008Est. completion: Oct 2010109 patients
Phase 3Completed
NCT00662220Rocheribavirin

High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4

Start: Apr 2008Est. completion: Nov 2013110 patients
Phase 3Terminated
NCT00411385Novartisalbumin interferon alfa-2b

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Start: Feb 2007Est. completion: Oct 2008933 patients
Phase 3Completed
NCT00402428Novartisalbumin interferon alfa-2b

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Start: Dec 2006Est. completion: Feb 20091,331 patients
Phase 3Completed
NCT00296972Rochepeg interferon plus ribavirin

Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication

Start: Jul 2005Est. completion: Apr 2007100 patients
Phase 3Terminated
NCT00162734Bausch HealthDaily Infergen

Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

Start: Feb 2005Est. completion: Jun 2007
Phase 3Completed
NCT00093093Bausch HealthViramidine

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

Start: Jun 2004Est. completion: May 2006
Phase 3Completed
NCT00086541Bausch HealthDaily Infergen

Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

Start: Jun 2004Est. completion: Jan 2007
Phase 3Completed
NCT00230958Bausch HealthViramidine

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive

Start: Dec 2003Est. completion: Jan 2006
Phase 3Completed
NCT00158496Rochepegylated interferon alpha2a

Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)

Start: Aug 2002Est. completion: Jan 2005100 patients
Phase 3Completed
NCT00144469Chugai Pharmapeginterferon alfa-2a

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C

Start: May 2002Est. completion: Mar 2005300 patients
Phase 3Completed
NCT02446717AbbVieABT-493, ABT-530

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Start: Apr 2015Est. completion: Jan 2017141 patients
Phase 2/3Completed
NCT02115321Merck & Co.Grazoprevir

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

Start: May 2014Est. completion: Jun 201540 patients
Phase 2/3Completed
NCT03501550Cocrystal PharmaCDI-31244

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Start: Jun 2018Est. completion: Jun 2019
Phase 2Completed
NCT02493855AbbVieOmbitasvir/ABT-450/Ritonavir

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Start: Jun 2015Est. completion: Dec 201646 patients
Phase 2Completed
NCT02292719AbbVieABT-450/r

A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection

Start: Dec 2014Est. completion: Jul 201770 patients
Phase 2Completed
NCT02202980Gilead SciencesLDV/SOF

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

Start: Aug 2014Est. completion: May 2016273 patients
Phase 2Completed
NCT02068222AbbVieABT-450/r

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Start: Apr 2014Est. completion: Mar 201510 patients
Phase 2Completed
NCT01949168Merck & Co.Victrelis®

A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV

Start: Sep 201330 patients
Phase 2Unknown
NCT01842451Vertex PharmaceuticalsVX-135

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Start: Jun 2013Est. completion: May 201423 patients
Phase 2Completed
NCT01859962Boehringer IngelheimPPI-668

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Start: May 2013Est. completion: Dec 201438 patients
Phase 2Completed
NCT01826981Gilead SciencesLDV/SOF

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Start: Apr 2013Est. completion: May 2015359 patients
Phase 2Completed
NCT01790100Vertex PharmaceuticalsVX-135

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Start: Feb 2013Est. completion: Jun 201420 patients
Phase 2Completed
NCT01726946Vertex PharmaceuticalsVX-135

A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Start: Nov 2012Est. completion: Feb 201410 patients
Phase 2Completed
NCT01455090Bristol Myers SquibbBMS-790052

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Start: Nov 2011Est. completion: Jul 2015320 patients
Phase 2Completed
NCT01051414Bristol Myers SquibbBMS-790052

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

Start: Apr 2010Est. completion: May 201243 patients
Phase 2Completed
NCT01012895Bristol Myers SquibbBMS-790052

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Start: Dec 2009Est. completion: Feb 2014215 patients
Phase 2Completed
NCT00943761Merck & Co.Vaniprevir 600 mg

A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)

Start: Oct 2009Est. completion: May 201345 patients
Phase 2Completed
NCT00759200Novartisalb-interferon alfa 2b

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Start: Oct 2008Est. completion: Dec 2010525 patients
Phase 2Completed
NCT00537407DebiopharmDebio 025

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Start: Sep 2007Est. completion: Apr 2010
Phase 2Completed
NCT00446134Bausch HealthTaribavirin

Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

Start: Mar 2007Est. completion: Apr 2009
Phase 2Completed
NCT00423670Merck & Co.boceprevir

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

Start: Jan 2007Est. completion: Nov 2008765 patients
Phase 2Completed
NCT00395421Merck & Co.valopicitabine

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Start: Oct 2006Est. completion: Aug 2008114 patients
Phase 2Completed

Related Jobs in Infectious Diseases

Executive Director, Global Medical Expert HIV Prevention - GMA Virology & Inflammation

Gilead Sciences
United States - Field
17h ago
$317K - $411K/yr

Sr. Engineer, Process Systems (Contract)

VaxCyte
Visp, Valais, Switzerland
20h ago

Director, Health Economics & Outcomes Research (HEOR)

VaxCyte
San Carlos, California, United States
22h ago
$242K - $282K/yr

Director U.S. Meningococcal Marketing

Pfizer
United States - New York - New York City
Yesterday
$177K - $294K/yr

Senior Manager, Contract Account Performance Specialist, Contract Strategy

Pfizer
Remote
Yesterday
$124K - $207K/yr

Scientist, Computational Vaccine Design

Metaphore Biotechnologies
Cambridge, MA USA
3d ago
$115K - $165K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

19 late-stage (Phase 3) programs — potential near-term approvals
19 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Covid19(79)HIV Infection(75)